Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.220
-0.090 (-2.09%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Cytek Biosciences Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 204.17 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 |
Revenue Growth | 3.61% | 0.52% | 3.85% | 17.67% | 28.20% | 37.82% |
Gross Profit Gross Profit Growth | 105.56 | 104.46 | 111.11 | 109.43 | 100.97 | 79.14 |
Operating Income Operating Income Growth | -43.87 | -40.38 | -20.52 | -27.85 | -1.8 | 9.16 |
Net Income Net Income Growth | -35.48 | -66.54 | -6.02 | -12.15 | 2.58 | 6.05 |
Earnings Per Share EPS Growth | -0.57 | -0.52 | -0.05 | -0.09 | 0.02 | - |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States United States Growth | 101.1 | 95.25 | 92.61 | 102.09 | 94.59 | 72.72 |
EMEA EMEA Growth | 55.08 | 55.88 | 62.34 | 53.18 | 43.96 | 36.97 |
APAC APAC Growth | 39.94 | 41.08 | 35.77 | 31.6 | 22.52 | 16.08 |
Other Other Growth | 8.05 | 9.28 | 9.73 | 6.15 | 2.96 | 2.18 |
Total Total Growth | 204.17 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 262.23 | 261.53 | 277.86 | 262.41 | 341.15 | 364.62 |
Total Debt Total Debt Growth | 13.83 | 14.57 | 8.6 | 11.13 | 14.58 | 0 |
Net Cash (Debt) Net Cash Growth | 248.4 | 246.96 | 269.26 | 251.28 | 326.57 | 364.62 |
Net Cash Growth | -3.44% | -8.28% | 7.15% | -23.05% | -10.44% | 120.67% |
Net Cash Per Share Net Cash Per Share Growth | 1.94 | 1.93 | 2.06 | 1.86 | 2.36 | 4.47 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -3.9 | -4.69 | 25.38 | 5.28 | -12.23 | 4.63 |
Capital Expenditures CapEx Growth | -5.4 | -4.08 | -3.53 | -4.65 | -9.75 | -4.36 |
Free Cash Flow Free Cash Flow Growth | -9.3 | -8.77 | 21.85 | 0.63 | -21.98 | 0.27 |
Free Cash Flow Growth | - | - | 3352.45% | - | - | -98.05% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 51.70% | 51.84% | 55.43% | 56.69% | 61.56% | 61.86% |
Operating Margin | -21.49% | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
Pretax Margin | -17.96% | -14.81% | -2.84% | -8.14% | 0.77% | 4.64% |
Profit Margin | -17.38% | -33.02% | -3.00% | -6.29% | 1.51% | 2.37% |
FCF Margin | -4.56% | -4.35% | 10.90% | 0.33% | -13.40% | 0.21% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 510.50 | - |
Forward PE | 172.84 | 89.56 | 26.14 | 245.06 | 44.39 | 152.95 |
P/FCF Ratio | - | - | 38.37 | 1883.29 | - | 8205.99 |
PS Ratio | 2.67 | 3.22 | 4.18 | 6.18 | 8.43 | 17.06 |